The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
 
Toni K. Choueiri
Honoraria - Alexion Pharmaceuticals; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Journal; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Healthcare; NCCN; NEJM; Novartis; Peloton Therapeutics; PER; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Journal; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Healthcare; NCCN; NEJM; Novartis; Paltform Q; Peloton Therapeutics; Peloton Therapeutics; Pfizer; Prometheus Laboratories; Roche/Genentech; Sanofi/Aventis; UpToDate
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Matthew T. Campbell
Honoraria - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Pfizer
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Pfizer
Research Funding - Exelixis (Inst)
 
Boris Y. Alekseev
No Relationships to Disclose
 
Motohide Uemura
No Relationships to Disclose
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Gwenaelle Gravis
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche; SANOFI
 
Georg A. Bjarnason
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Merck; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Howard Gurney
Honoraria - Astellas Pharma; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck Sharp & Dohme
Research Funding - Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Sanofi
 
Jinsoo Chung
No Relationships to Disclose
 
John B. A. G. Haanen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst)
 
Brian I. Rini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Merck; Pfizer
 
James M. G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOnctura; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOnctura; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Manuela Schmidinger
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Novartis; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Novartis; Pfizer; Roche
 
Franco Nole
No Relationships to Disclose
 
Aleksander Chudnovsky
Employment - Pfizer
 
Bo Huang
Employment - Pfizer
 
Subramanian Hariharan
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Alessandra di Pietro
Employment - Pfizer
 
Laurence Albiges
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); Novartis; Novartis (Inst); Pfizer (Inst); Roche (Inst)